Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in Europe. This trial aims for a comparison of the efficacy and safety of Insulin Aspart, given in a fixed or in a flexible supplementary insulin therapy, with or without Insulin Detemir plus Metformin, if needed, in subjects with type 2 diabetes.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 Diabetes for more than 6 months
Treatment with 1 or more oral anti-diabetic drugs or insulin, or a combination of these for more than 3 months
Body Mass Index (BMI) less than or equal to 40 kg/m2
Treatment with short acting insulin(s) for longer than 10 days
Current treatment with TZDs. A TZD medication must be stopped at least 14 days before the randomization
Proliferative retinopathy or maculopathy requiring acute or laser treatment within the last 6 months